AbbVie to Acquire Apogee Therapeutics
AbbVie plans to acquire Apogee Therapeutics, expanding its immunology portfolio with a diverse pipeline of innovative therapies for dermatologic, respiratory, inflammatory, and immune-mediated diseases.
Michael Henderson | 23/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy